All Becton, Dickinson and Company articles
-
News BriefBecton Dickinson pays $175M for misleading investors about flawed IV pump system
Becton Dickinson medical device company will pay $175 million for “repeatedly” misleading investors about its Alaris infusion pump, a product the company knew was flawed and was sold without the required patient-safety approvals, the Securities and Exchange Commission said.
-
Blog
Becton, Dickinson & Co. promotes CECO to general counsel
Global medical technology firm Becton, Dickinson and Company announced the promotion of Chief Ethics and Compliance Officer Michelle Quinn to general counsel.